Free tool
FAERS Monitor: Mepron
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020500 or its brand name (Mepron, Atovaquone). Reports on generic versions are filed under their own applications.
Reports
8,218
Serious
7,018
85% of reports
Hospitalization
4,183
Death reported
1,382
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use833
- pyrexia453
- diarrhoea435
- drug ineffective426
- nausea406
- pneumonia393
- death323
- fatigue313
- dyspnoea298
- acute kidney injury292
- neutropenia279
- condition aggravated278
- rash276
- vomiting272
- thrombocytopenia269
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 42 |
| 2005 | 52 |
| 2006 | 52 |
| 2007 | 60 |
| 2008 | 82 |
| 2009 | 105 |
| 2010 | 90 |
| 2011 | 89 |
| 2012 | 126 |
| 2013 | 134 |
| 2014 | 170 |
| 2015 | 209 |
| 2016 | 240 |
| 2017 | 272 |
| 2018 | 373 |
| 2019 | 403 |
| 2020 | 570 |
| 2021 | 668 |
| 2022 | 836 |
| 2023 | 956 |
| 2024 | 993 |
| 2025 | 986 |
| 2026 | 710 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,941 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| thrombocytopeniaSignal | 269 | 6.2 | 5.5 | 1,163 |
| neutropeniaSignal | 279 | 5.3 | 4.7 | 963 |
| acute kidney injurySignal | 292 | 4.9 | 4.4 | 905 |
| pyrexiaSignal | 453 | 3.4 | 3.1 | 757 |
| pneumoniaSignal | 393 | 3.1 | 2.8 | 568 |
| off label useSignal | 833 | 2.4 | 2.3 | 734 |
| condition aggravatedSignal | 278 | 2.3 | 2.1 | 215 |
| diarrhoea | 435 | 1.7 | 1.6 | 136 |
| rash | 276 | 1.6 | 1.4 | 66 |
| vomiting | 272 | 1.5 | 1.3 | 43 |
| dyspnoea | 298 | 1.3 | 1.2 | 27 |
| nausea | 406 | 1.3 | 1.2 | 31 |
| fatigue | 313 | 1.0 | 0.9 | 0 |
| death | 323 | 1.0 | 0.9 | 1 |
| drug ineffective | 426 | 0.8 | 0.8 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.